|
NSQ list for September includes samples from major cos, PSUs
|
|
Gireesh Babu, New Delhi
October 27 , 2025
|
|
|
The 112 Not of Standard Quality (NSQ) drug samples declared by the Central Drugs Standard Control Organisation (CDSCO) for the month of September, 2025 following tests conducted by both the central and the state drug testing laboratories include samples from drug majors including Zydus Healthcare, Hetero Labs, and Macleods Pharma, along with samples from two public sector undertakings.
Nine samples each from two companies were identified as NSQ by the drug regulators during the month, apart from multiple samples manufactured by many other companies failing the quality test during the month, according to data from the CDSCO.
Almost 11 states and several Union Territories (UTs) in the country did not submit the NSQ data with the CDSCO within the specified timeframe, according to data from the central drug regulator.
According to the regulator, sample of diclofenac sodium and paracetamol tablets from Zydus Healthcare, Sikkim unit, failed the quality test conducted by the State lab of the Government of National Capital Territory of Delhi. The company's name has been listed one more time in the NSQ list released for September, but the product and the batch number are the same as once listed.
A sample of ivabradine tablets 5 mg from Hetero Labs, Himachal Pradesh unit, has also been declared as NSQ, after tested in the Sate laboratory of Government of Goa. A sample of clobetasol propionate neomycin sulphate and miconazole nitrate cream from Macleods Pharmaceuticals, Sikkim, has also been listed after the state laboratory of Chhattisgarh remarked it as spurious, according to the digital data released by the CDSCO.
One sample each from the public sector undertakings Hindustan Antibiotics Ltd, and Karnataka Antibiotics and Pharmaceuticals Ltd, were also declared as NSQs during the month.
Nine samples of products from Affy Parenterals, Himachal Pradesh, tested by the state laboratories of Chhattisgarh and Jammu and Kashmir, were declared as NSQ.
Similarly, nine samples of products from Gidsha Pharmaceuticals, Gujarat, tested by the central drug laboratories during the month were also declared as NSQ.
Six samples from R.P. Biotech, Punjab were declared as NSQ by the Central laboratories. Two to three samples of several other companies were also declared as NSQs by the drug testing laboratories during the month.
According to the data shared by the CDSCO, States of Arunachal Pradesh, Assam, Bihar, Jharkhand, Kerala, Manipur, Mizoram, Nagaland, Odisha, Tamil Nadu, and Tripura did not submit any data in respect of NSQ alert for the month of September, 2025.
The UTs of Andaman and Nicobar, Dadra and Nagar Haveli; Daman and Diu, Ladakh, Lakshadweep, Puducherry, and Chandigarh, also did not submit the data to the CDSCO, says the digital data.
Out of the total 112 samples that failed the tests during the month, 52 were identified in the Central Drugs Laboratories, while 60 were identified by the State Drugs Testing Laboratories.
"Identification of drug samples as NSQ is done based on failure of the drug sample in one or the other specified quality parameters. The failure is specific to the drug products of the batch tested by the government laboratory and it does not warrant any concerns on the other drug products available in the market," said the authority.
Besides, in September, one drug sample of Besto-Cof drug cough formula tested by the state of Chattisgarh was identified as a spurious drug, which was manufactured by an unauthorized manufacturer using a brand name owned by another company. The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug.
The matter is under investigation and action will be taken as per Act & Rules, said the CDSCO.
"This action of identifying NSQ and Spurious medicines is taken on a regular basis in collaboration with state regulators to ensure that these drugs are identified and removed from the market," it added.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|